15 Comments
 

Thank you guys for inputting so far.

RC very strong for sure. Interested in hearing more about deal size, as far as I am aware RC v good for volume. IK CVP and PJT dominate biopharma mega deals in US. Interested in hearing about UK/Europe from a HC mega deal perspective too

 
Most Helpful

Quick overview of Europe: 

Evercore's pretty decent - they did AstraZeneca / Alexion + a few other deals, fair mix between sell and buy sides. 

CVP is good for biotech sell sides (in the US), they were also involved in AstraZeneca / Alexion + I think they're trying to replicate that franchise here in Europe. They've been involved in a sell sides here. 

Not sure why you mentioned PJT here - not sure what they do here in Europe. (AbbVie / Allergan doesn't count even though Allergan is "Irish") 

Rothschild and Jefferies are volume shops - predominately PE sell sides. Quick Linkedin search of their profiles and you'd realize they have relatively better PE exits than the aforementioned 3 shops 

From Mergermarket (excluding the BBs, Big4 and MM players, including the generally accepted "EBs" + Jefferies), Target / Acquirer: Europe, Date: 01/01/19 - 14/2/21 (sorted by deal size)

1. Evercore

2. PJT

3. CVP

4. Roths

5. Lazard

6. Jefferies

7. Moelis

Array
 

Wasn't EVR on the buy-side on those deals if I recall? i.e. less fees - how are they number 1?

I think this is very inaccurate...

CVP was on the sell-side of most the mega deals this year. One of their partners, Richard Girling (London partner) is a beast in HC . Also Rothschild and Laz did way better than EVR this year as well.

Dont know much about the rest so can't comment, but EVR as number 1 in London is a joke... Yes they're respected, did a lot better in 2019 than this year, but definitely not number one, they did poor from a fee perspective. 

 

Minus amet ut suscipit maxime velit quia mollitia. Ipsum voluptatem porro omnis accusantium.

Cupiditate libero officiis maiores rerum id. Vel aut reiciendis et omnis harum tempora eligendi et. Minus blanditiis saepe cum sequi. Enim accusantium et est voluptate suscipit non.

Ut occaecati quod excepturi. Laborum soluta a molestiae quo.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (67) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
DrApeman's picture
DrApeman
98.9
7
GameTheory's picture
GameTheory
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
dosk17's picture
dosk17
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”